{'fraction_non_alphanumeric': 0.05942622950819672, 'fraction_numerical': 0.03790983606557377, 'mean_word_length': 4.921212121212121, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Determination of Glycated Apolipoprotein B in Serum by a Combination of Affinity Chromatography and Immunonephelometry

We have developed and optimized a procedure for the quantitation of non-enzymatically glycated apolipoprotein B (apo B). Glycated and non-glycated apo B were separated from serum using m-aminophenylboronate affinity chromatography, determined by immunophelometry and the percentage of glycated apo B was calculated. The measuring range of the assay was 2·9–185 mg/dL apo B. The within- and between-run coefficients of variation were <7·4% and 14·6%, respectively, and recovery was >98%. Free glucose in serum did not affect the results at concentrations below 25 mmol/L. In 45 non-diabetic subjects the mean concentration of glycated apo B was 4.3% (SD 1%). In type 1 (n = 17) and Type 2 (n = 60) diabetic patients the mean glycated apo B concentrations were 5·3% (SD 0·7%) and 5·9% (SD 1·1%), respectively, significantly higher than in controls (P<0·001).